Enhancer RNA Transcription Is Essential for a Novel CSF1 Enhancer in Triple-Negative Breast Cancer

Public Deposited
Analytics

Downloadable Content

Download PDF
Request Version for Screen Reader
Creator
  • Lewis, Michael W.
    • N.C. Cancer Hospital, UNC Lineberger Comprehensive Cancer Center
  • Wisniewska, Kamila
    • N.C. Cancer Hospital, UNC Lineberger Comprehensive Cancer Center
  • King, Caitlin M.
    • N.C. Cancer Hospital, UNC Lineberger Comprehensive Cancer Center
  • Li, Shen
    • N.C. Cancer Hospital, UNC Lineberger Comprehensive Cancer Center
  • Coffey, Alisha
    • N.C. Cancer Hospital, UNC Lineberger Comprehensive Cancer Center
  • Kelly, Michael R.
    • N.C. Cancer Hospital, UNC Lineberger Comprehensive Cancer Center
  • Regner, Matthew J.
    • N.C. Cancer Hospital, UNC Lineberger Comprehensive Cancer Center
  • Franco, Hector L.
    • N.C. Cancer Hospital, UNC Lineberger Comprehensive Cancer Center
Abstract
  • Enhancers are critical regulatory elements in the genome that help orchestrate spatiotemporal patterns of gene expression during development and normal physiology. In cancer, enhancers are often rewired by various genetic and epigenetic mechanisms for the activation of oncogenes that lead to initiation and progression. A key feature of active enhancers is the production of non-coding RNA molecules called enhancer RNAs, whose functions remain unknown but can be used to specify active enhancers de novo. Using a combination of eRNA transcription and chromatin modifications, we have identified a novel enhancer located 30 kb upstream of Colony Stimulating Factor 1 (CSF1). Notably, CSF1 is implicated in the progression of breast cancer, is overexpressed in triple-negative breast cancer (TNBC) cell lines, and its enhancer is primarily active in TNBC patient tumors. Genomic deletion of the enhancer (via CRISPR/Cas9) enabled us to validate this regulatory element as a bona fide enhancer of CSF1 and subsequent cell-based assays revealed profound effects on cancer cell proliferation, colony formation, and migration. Epigenetic silencing of the enhancer via CRISPR-interference assays (dCas9-KRAB) coupled to RNA-sequencing, enabled unbiased identification of additional target genes, such as RSAD2, that are predictive of clinical outcome. Additionally, we repurposed the RNA-guided RNA-targeting CRISPR-Cas13 machinery to specifically degrade the eRNAs transcripts produced at this enhancer to determine the consequences on CSF1 mRNA expression, suggesting a post-transcriptional role for these non-coding transcripts. Finally, we test our eRNA-dependent model of CSF1 enhancer function and demonstrate that our results are extensible to other forms of cancer. Collectively, this work describes a novel enhancer that is active in the TNBC subtype, which is associated with cellular growth, and requires eRNA transcripts for proper enhancer function. These results demonstrate the significant impact of enhancers in cancer biology and highlight their potential as tractable targets for therapeutic intervention.
Date of publication
Keyword
DOI
Identifier
Resource type
  • Article
Rights statement
  • In Copyright
License
  • Attribution 3.0 United States
Journal title
  • Cancers
Journal volume
  • 14
Journal issue
  • 7
Page start
  • 1852
Language
  • English
Version
  • Publisher
ISSN
  • 2072-6694

Relations

Parents:

This work has no parents.

In Collection:

Items

Thumbnail Title Date Uploaded Visibility Actions
file details cancers-14-01852-v2.pdf 2022-05-03 Public Download